Get the Stockscreener App
14.57
0.55%
0.08
After Hours:
14.28
-0.29
-1.99%
Pulse Biosciences Inc stock is traded at $14.57, with a volume of 177.60K.
It is up +0.55% in the last 24 hours and up +2.32% over the past month.
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled.
See More
Previous Close:
$14.49
Open:
$14.54
24h Volume:
177.60K
Relative Volume:
1.05
Market Cap:
$987.37M
Revenue:
$-9,000
Net Income/Loss:
$-68.03M
P/E Ratio:
-13.88
EPS:
-1.05
Net Cash Flow:
$-44.76M
1W Performance:
-0.21%
1M Performance:
+2.32%
6M Performance:
-9.11%
1Y Performance:
-21.09%
1-Day Range:
$13.85
$14.75
1-Week Range:
$13.85
$15.64
52-Week Range:
$12.56
$25.00
Pulse Biosciences Inc Stock (PLSE) Company Profile
Name
Pulse Biosciences Inc
Sector
Industry
Phone
510-906-4600
Address
3957 POINT EDEN WAY, HAYWARD, CA
Compare PLSE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLSE
Pulse Biosciences Inc
|
14.57 | 981.95M | -9,000 | -68.03M | -44.76M | -1.05 |
|
ISRG
Intuitive Surgical Inc
|
572.75 | 207.82B | 9.61B | 2.77B | 2.27B | 7.555 |
|
BDX
Becton Dickinson Co
|
202.74 | 57.77B | 21.84B | 1.68B | 2.67B | 5.8293 |
|
ALC
Alcon Inc
|
80.86 | 39.36B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
RMD
Resmed Inc
|
257.84 | 36.85B | 5.26B | 1.44B | 1.76B | 9.7713 |
|
MDLN
Medline Inc
|
42.72 | 31.89B | 27.43B | 1.27B | 1.01B | 1.5829 |
Pulse Biosciences Inc Stock (PLSE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-07-25 | Initiated | Oppenheimer | Outperform |
| Jul-27-21 | Initiated | Stephens | Overweight |
| Mar-11-21 | Initiated | Maxim Group | Buy |
| Jan-26-21 | Reiterated | H.C. Wainwright | Buy |
| May-12-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Feb-14-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Feb-25-19 | Initiated | H.C. Wainwright | Buy |
View All
Pulse Biosciences Inc Stock (PLSE) Latest News
New Cardiac Ablation Data and Board Appointment Might Change The Case For Investing In Pulse Biosciences (PLSE) - simplywall.st
How Investors May Respond To Pulse Biosciences (PLSE) AF Data Reveal And Boardroom Refresh - Yahoo Finance
How buybacks impact Pulse Biosciences Inc. stock valueEarnings Recap Summary & Free Verified High Yield Trade Plans - ulpravda.ru
Will Pulse Biosciences Inc. stock outperform tech sector in 20252025 Geopolitical Influence & Verified Trade Idea Suggestions - ulpravda.ru
Will Pulse Biosciences Inc. (6L8) stock profit from automation wave2025 Key Highlights & Entry Point Confirmation Signals - ulpravda.ru
Pulse Biosciences appoints healthcare veteran Maria Sainz to board By Investing.com - Investing.com Nigeria
Pulse Biosciences, Inc. Appoints Maria Sainz to its Board of Directors - 01net
Pulse Biosciences Adds Veteran Healthtech Leader to Board - TipRanks
Pulse Biosciences Elects Maria Sainz to Board of Directors - TradingView — Track All Markets
Can Pulse Biosciences Inc. stock continue upward trendPortfolio Performance Summary & Growth Focused Entry Reports - ulpravda.ru
Weekly Earnings: Will Pulse Biosciences Inc. (6L8) stock outperform value peersEarnings Overview Summary & Growth Focused Entry Reports - ulpravda.ru
Will Pulse Biosciences Inc. stock reach Wall Street targetsMarket Trend Review & Real-Time Volume Trigger Notifications - ulpravda.ru
Is MBX Biosciences Inc. stock positioned well for digital economyJuly 2025 Short Interest & Safe Entry Momentum Tips - ulpravda.ru
Why Pulse Biosciences Inc. stock remains resilient2025 Key Lessons & Daily Stock Momentum Reports - ulpravda.ru
Can Pulse Biosciences Inc. (6L8) stock deliver double digit returnsMarket Weekly Review & Safe Capital Allocation Plans - ulpravda.ru
Pulse Biosciences Selected to Present Late-Breaking Data from the nPulse Cardiac Catheter Study at the AF Symposium - Bluefield Daily Telegraph
(PLSE) Volatility Zones as Tactical Triggers - Stock Traders Daily
Working capital per share of Pulse Biosciences, Inc. – DUS:6L8 - TradingView — Track All Markets
What analysts say about Pulse Biosciences Inc 6L8 stockEarnings Growth Projections & Test Our Stock Screener — Free Forever - Early Times
Chipmakers Recap: How Pulse Biosciences Inc 6L8 stock responds to bond market - moha.gov.vn
Pulse Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference - Bluefield Daily Telegraph
Total debt per share of Pulse Biosciences, Inc. – MUN:6L8 - TradingView — Track All Markets
Positron (OTCMKTS:POSC) vs. Pulse Biosciences (NASDAQ:PLSE) Critical Comparison - Defense World
What drives Pulse Biosciences Inc 6L8 stock priceHigh Dividend Yield Stocks & High Profit Market Growth - earlytimes.in
MSN Money - MSN
Understanding the Setup: (PLSE) and Scalable Risk - Stock Traders Daily
Pulse Biosciences (PLSE): Valuation Check After FDA IDE Approval for nPulse Cardiac Ablation Trial - Sahm
Pulse Biosciences Updates Investors on Product Advancements - MSN
Pulse Biosciences, Inc (PLSE) Investor Outlook: Exploring A 44.74% Potential Upside - DirectorsTalk Interviews
Why Pulse Biosciences (PLSE) Is Up 8.0% After FDA Clears Pivotal Atrial Fibrillation Trial - Sahm
Pulse Biosciences holds 2025 annual stockholder meeting - MSN
Pulse Biosciences (NASDAQ:PLSE) Is In A Good Position To Deliver On Growth Plans - Sahm
Can Pulse Biosciences Inc. stock beat market expectations this quarterEarnings Recap Report & Growth Focused Stock Reports - Улправда
What technical signals suggest for Pulse Biosciences Inc. stockSell Signal & AI Driven Price Forecasts - Улправда
Pulse Biosciences announces inducement grants under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Market Pulse: How Aura Biosciences Inc. stock performs in high volatility marketsWall Street Watch & Long-Term Safe Investment Ideas - Улправда
Aug Fed Impact: Can Pulse Biosciences Inc. (6L8) stock deliver double digit returnsQuarterly Growth Report & Free Weekly Chart Analysis and Trade Guides - Улправда
PLSE Wins FDA IDE Approval to Launch nPulse AF Ablation Study Trial - sharewise.com
How Pulse Biosciences Inc. stock responds to policy changesMarket Risk Summary & Daily Risk Controlled Trade Plans - DonanımHaber
Can Pulse Biosciences Inc. stock resist market sell offs2025 Support & Resistance & Community Verified Trade Signals - DonanımHaber
FDA approves Pulse Biosciences’ atrial fibrillation trial By Investing.com - Investing.com Australia
How Pulse Biosciences Inc. stock benefits from tech adoptionMarket Sentiment Report & Consistent Profit Trading Strategies - DonanımHaber
Short Covering: Can Pulse Biosciences Inc. stock beat market expectations this quarter2025 Top Decliners & Long-Term Growth Plans - Улправда
Pulse Biosciences wins FDA approval to begin PFA catheter study - MedTech Dive
Pulse Biosciences gains FDA IDE for NANOPULSE-AF trial - TipRanks
Pulse Biosciences IDE Approval for Atrial Fibrillation Study - TradingView — Track All Markets
[8-K] PULSE BIOSCIENCES, INC. Reports Material Event | PLSE SEC FilingForm 8-K - Stock Titan
Pulse Biosciences Receives FDA Approval to Launch Cardiac Catheter Ablation Study - marketscreener.com
Pulse Biosciences Announces FDA IDE Approval to Initiate its nPulse Cardiac Catheter Ablation System Study for the Treatment of Atrial Fibrillation - Investing News Network
FDA approves Pulse Biosciences’ atrial fibrillation trial - Investing.com
Pulse Biosciences Inc Stock (PLSE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.46%
5.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):